Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
4500 shares at .046… a whopping $200 transaction. Who the hell cares? This is just pointless FUD and/or complaining. Either that or someone with a complete lack of understanding of the fluctuations you see on a low volume, low float stock.
And no surprise you don’t come back to mention the 20,000 shares that traded at .059 afterwards (and the current last price). But I suppose that’s how it goes when you look at everything through brown-colored glasses.
ALRT is absolutely KILLING it! 046. Maybe better luck next year... again.
Sorry - Please disregard my previous post. Mr. Chan is in Singapore not Shanghai. Obviously I am globally challenged!
Wonder if the lock-down situation in Shanghai is impacting ALRT and more specifically impacting our CEO's ability to push ALRT forward.
Pretty solid week. Hopefully something is brewing with the partnership.
Have good weekends.
If only 0.01% of your posts spinning stories of riches were just around the corner these last 4 years were true, you'd make Elon Musk look poor.
And people like you keep telling investors that it's "dollar land any day now" for years on end with nothing ever to show for it but cheap talk.
I didn’t read the entire 10q was there any significant info That would have caused the volume spike? I was surprised by the amount of info disclosed on the report… wondering if the prospective partner required them to disclose all that info before they announce a partnership .. either way can’t remember the last time we did a million shares traded.. at least not since the fda news
Hahaha! I think you are 100% correct! Just wishful thinking on my part.
Either way. I couldn't agree more. These things take time, but it seems Mr. Chan is putting all the right pieces of the puzzle together while navigating through this all. I for one actually appreciate throughout this process there has not been any pump and dump going on like you see with other OTC stocks. Makes me more of a believer, although I know the risk involved with start-ups. As things progress I do hope some bigger fish take notice and start investing in ALR to gradually get the share price up, but by doing it the right, and consistent way so that we don't see the extreme swings . We still have a ways to go I believe, but I do feel we are on the right track!
Good to see volume picking up. Hopefully hear something on the partnership in the next month or two.
It has been mentioned in several recent pr's and I personally believe Chan and his team will deliver.
When partnership news comes the stock price is going to go berserk. Glad to see people starting to load
Nice to see somewhat of consistent volume these past few days. Hopefully something significant is brewing behind the scenes. From what I have gathered trying to catch up here, it seems mckvee has a sell order on all $5,000 worth of his shares at .07-.08. With all the complaining he constantly does, I truly hope he is a man of his word and still has this sell order in place! Even if it only hits this price for a few minutes and goes back down. Haha! Would just love to see him hit his extremely high price target and move on to the next penny stock he can moan and gripe about! Lol!
A couple high volume days in a row, wonder what that means, would we see the options as volume?
My wife has more revenue selling stuff on Facebook marketplace.
I went back to Post #1 for ALRT - 12-1/2 YEARS AGO!
12,000 posts later, same problem today as then. Missing revenues! LOL. But "dollar-land" coming any day now! Sure it is.
_________________________________________________________________
tomcat17
Monday, October 05, 2009 9:01:04 AM
Re: None
Post #1 of 12312
"ALRT has the patent for its medical device but is falling and falling. Why? Anyone a guess? Revenues missing?"
Dollar-land any day now! LOL.
Thats $27 dollars well spent!
Yeah couldn't agree more, ultimately it is the revenues that will make ALRT a multi-dollar stock. The OTC markets use market makers so most of your big investors (banks, institutional, funds) can't invest, but if they uplist to the AMEX, AMEX uses exchanges like the NYSE and nasdaq so all can invest. That is obviously a bit further off, but in the next month or two if they close a pharmaceutical partnership the name alone would shoot the price up. But if they announce how much they are selling the 50% stake for and it is 10s of millions or 100s of millions then we could break a dollar in a day IMO.
The fact that there are only 109 million shares trading in the float also makes it easy to move with a partnership news.
Another great pr and a pretty good day. This quote right here is going to move the pps. They have mentioned the partnership agreement in several pr's. Personally, I do not see Chan allowing it to be mentioned multiple times unless there is a very high probability of putting the agreement together.
Good luck to Mr. Chan and his team. Hopefully the next PR is in regards to the partnership agreement.
"well positioned to start realizing the full potentials of ALRT. We will now focus our attention on completing a partnership agreement in the near future to commercially launch GluCurve Pet CGM in a meaningful way”
Sounds like you are onto something Goldy, for sure worth additional research. They extended the offering deadline again. No surprise given current pps.
At the last offering I added a bunch of shares to my position. Shares I really cant afford right now but I came up with the money to take advantage.
The offering allows you to add shares easily, efficiently, quickly with out running the price up.
Very nice reply Goldy, and thank you. Yes, I'm aware of Section 1202 qualified gain exclusion, and you are correct in that subscription rights purchase should be considered original issue so there's more to this than looking strictly at share price.
I think the issue with at least some of us shareholders is the year-after-year hype with no revenue deals in place. Once again we are being told 2022, possibly 2023 for a deal to take place. Had this been, say, 3 or 4 years ago and only my second bite at the apple, I probably would have jumped on the opportunity, regardless of PPS (within reason). I've done similar in the past.
But after 5 years now and having gone through many cycles of "dollar-land any day now" hype with no dollar-land or anything close coming to fruition, not too excited about the offering - especially at or higher than current PPS. Sort of like dollar averaging on a falling stock price trying to catch a falling knife... whose price never comes back up. You reach a point where you have to say to yourself, "Am I just throwing good money after bad?". That's where many of us are with ALRT. But again, thanks for the thoughtful msg. And who knows... maybe the next time (if) the Rights come around again, I'll jump on it. LOL. GLTU!
News! ALR Technologies Announces Completion of Pivotal Non-Inferiority Study on the GluCurve Pet CGM
March 15, 2022 08:28 ET | Source: ALR Technologies
SINGAPORE, March 15, 2022 (GLOBE NEWSWIRE) -- ALR Technologies Inc. (“ALRT” or the “Company”) (OTCQB: ALRT), the diabetes management company, today announced successful results from the conclusion of the non-inferiority study conducted on the GluCurve Pet CGM which was previously announced on February 10, 2022 and February 28, 2022. GluCurve is the first of its kind Continuous Glucose Monitor (CGM) specifically for diabetic cats and dogs.
Notable findings from the study:
Utilizing a chemistry analyzer as the baseline, the GluCurve Pet CGM was more accurate than the leading Blood Glucose Meter (BGM) for animals 47.8% of the time.
100% of the GluCurve Pet CGM readings paired to the chemistry analyzer reference values were within ±20%, compared to 86.9% from the animal BGM
The GluCurve Pet CGM’s average deviation from the baseline was 9.7% compared to 8.2% from the animal BGM.
No clinically significant differences were found when comparing the GluCurve Pet CGM to the chemistry analyzer or leading animal BGM.
GluCurve displayed otherwise unavailable data on insulin injection times, eating habits, activity, and stress seen through changes in glucose on a day-to-day basis.
Dr. Imperato, lead veterinarian in the study commented, “The GluCurve Pet CGM plugs a long-standing gap in managing veterinary diabetic patients; not only will veterinarians finally receive effortlessly accurate data, the patients will live longer too.”
“The non-inferiority study further demonstrates the significant need for GluCurve in veterinary medicine. The in-home data collected is invaluable to veterinarians and by analyzing and organizing it into effective patient management it greatly reduces the effort and time needed by clinicians to treat diabetic pets,” said Sidney Chan, Chairman and CEO of ALR Technologies. “Now that we have the successful results of the non-inferiority study, a MOU for manufacturing with a definitive agreement in the works, and conducted preliminary discussions with the leading animal health pharmaceutical companies, we are well positioned to start realizing the full potentials of ALRT. We will now focus our attention on completing a partnership agreement in the near future to commercially launch GluCurve Pet CGM in a meaningful way in Q3 2022.”
About ALR Technologies
ALR Technologies is a data management company that developed the ALRT Diabetes Solution, a comprehensive approach to diabetes care that includes: an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices; a patent pending Predictive A1C algorithm to track treatment success between lab reports and an FDA-cleared Insulin Dosing Adjustment program. ALRT also offers an algorithm to provide prescribers support for timely non-insulin medication advancements. The overall goal is to optimize diabetes drug therapies to drive improved patient outcomes. The program tracks performance of all clinical activities to ensure best practices are followed. The ALRT Diabetes Solution gives healthcare providers a platform for remote diabetes care, helping to minimize patient exposure to potential infections in clinical settings. Currently, the Company is focused on diabetes and will expand its services to cover other chronic diseases anchored on verifiable data.
In addition, the animal health division has identified an unmet need in diabetes care and has developed GluCurve; a solution to assist Veterinarian Doctors to determine the efficacy of insulin and to help to identify the appropriate dose and frequency of administration of insulin for companion animals. Thus, delivering the same optimization of diabetic drug therapies to pets as to humans.
On June 1, 2021, ALR Technologies Inc. announced its intention to migrate to Singapore. More information about ALR Technologies Inc. can be found at www.alrt.com. Information regarding ALR Technologies SG Pte. Ltd. can be found at https://sg.alrt.com.
Long time lurker, first time poster.
It's true the subscription right may be the same or lower then the current market price for the stock. However, if a right holder sees any value in adding to their position, they would be wise to consider exercising the right - as opposed to buying shares on the open market (at least speaking from the perspective of a US Taxpayer).
Check out Section 1202 of the Internal Revenue Code - "Partial Exclusion from Gain for Certain Small Business Stock"
There are many requirements needed to qualify for this exclusion. But the biggest/hardest one, in my opinion, is having a position that qualifies as "original issue". Buying on the secondary market is not "original issue", but a Rights offering, sounds like an "original issuance" to me. It's not often you can get an opportunity to acquire an "Original Issue" stock, so it may be worthwhile to pay a premium on the exercise (if there is a premium at all) to potentially qualify for this gain exclusion in the future.
I'm not an investment advisor/1202 expert, just a normal guy who invests in stocks. So you obviously have to consult your own advisory team/do your own due diligence. But I just wanted to share this to provide some food for thought.
Who knows. Maybe Chan knows it does qualify and he keeps trying to give the stockholders an opportunity to get in (continually re-opening/extending the rights offerings)?? Wishful thinking most likely, but maybe it's not...
Meanwhile, the share price is still below the subscription rights offer and there's little interest in this company. Obviously, if Chan ever gets a significant revenue deal that will all change. But that's still a big "if".
At this point I want to take my money out and put it into some movers, but will take weeks to sell all for a loss
Good post, I couldn't agree more
First of all, LOS' pet population with diabetes is off by a factor of 2. Considering there are approximately 76.8M dogs and 58.4M cats in the US, and it is estimated that 1 in 300 dogs and 1 in 230 cats have diabetes, that amounts to roughly 0.5M dog and cat "pets" that even have diabetes... not 1.0M. As far as other pets like birds, ferrets, and the like.. forget about that.
Then, one has to take in consideration not 100% of these pet owners are going to even know their animal has diabetes, let alone treat them for it. Not to mention that many of the dogs and cats in this country are strays. ALRT will be lucky to capture 10% of this 0.5M population, even if they had 100% market share.
All of this is besides the point and you nailed it on the head. It's about the hype with these OTC's and I question the money being spent these past 5 years as well. LOS asks why we hang in there and haven't divested ourselves of our shares yet if we lack confidence in the company? He knows the answer to that. First of all, the trade volume is non-existent and trying to dump a 1/4 mil, 1/2 a mil, or millions of shares only drives the PPS way down and begs the investor to take a significant hit. Then, there's that "hope" that someday Chan & Co. will make "the deal" and we'll be able to recoup our investments or make a reasonable profit for hanging onto a speculative company this long.
I've bought into the cheer-leading on these OTC's too often. And ALRT is the last one for me. For everyone of these speculative companies that hit, 1,000 of them fail. And all the hype and cheer-leading in the world doesn't change that fact.
23 x 750k = about the same as ALRT. And developing software for consumer product companies is way easier route than seeking pharma and FDA approvals. Seeking partnerships takes time as well. I’m ok where we are now. Let’s go ALRT.
23 x 750k = about the same as ALRT. And developing software for consumer product companies is way easier route than seeking pharma and FDA approvals. Seeking partnerships takes time as well. I’m ok where we are now. Let’s go ALRT.
Best thing for the company would be to license their a1c predictive patent. Might be the only way we get revenue. If the company wants to be in vet clinics that a really hard thing. It isn't like hospital networks where one group owns multiple hospitals. It will cost millions to market to the vet clinics and years to get real adoption. My wife makes more revenue selling stuff on Facebook marketplace.
I've given up on OTC research, it's all about hype and this company lost it's hype right after FDA approval. Also I don't get how keeping this company afloat cost 20mil over 5 years, they spent 4mil a year and just have a phone app. A kid in college would build this app for 100k.
Market data means nothing if you haven't even entered the market.
How could somebody spend so much time complaining yet so little time researching the company they are complaining about? It is truly astounding.
There are only two companies selling CGMs (since Medtronic is basically out of the picture), Abbott and Dexcom. Dexcom is 4x the cost of Libre and priced out of the animal market and Libre will not sell to veterinarians or make an animal CGM. Literally one phone call to a veterinarians or one google search would tell you that information in minutes.
So please tell me what "big player" is going to spend a million dollars creating software for the next year and then when they do that please tell me how they are going to sell a CGM? Find me one manufacturer they could partner with anywhere in the world.
Just looking at the USA alone, there are 1 million diabetic animals. With no competition. ALRT will have 100% of the market as the ONLY pet cgm. If the animals use it 3 times a year that is 3,000,000 times $x amount of profit. If they even make $10 that is $30,000,000 and I assume they will make a lot more then that.
If you don't believe the animal market will make money you're a fool for staying invested in a company you think will fail. And if you do think it will make money why are you crying?
Rdizz - so did I, today. Not interested in 05 a share or in financing any more of Mr. Chan's debt. What I am interested in, after 5 years of holding this, is getting a damn return on my investment.
I can't believe it's costing 20mil to develop and sell a software product. I'm a developer with 10yrs experience. I was developing software for Aldi through a consulting firm for 7 of those years. My company only billed around $750k a year to them with 4 developers billing. What they have would take less than a year to replicate. The big players can hire two devs for $300k a year and catch up in no time
Just saw the rights offering in my brokerage account, anyone thinking of paying off chan's debt to the company haha
Perhaps the old Aesop fable "The Boy Who Cried Wolf" comes to mind, and can help explain why the latest PR didn't move the needle on share price. Just saying... GLTUA
Looking forward to the end of this month when we should see another PR about the Pet CGM partnership. I’m not worried, but am miffed that there isn’t more interest in this stock. The last PR was really exciting news. Keep up the good work, Mr Chan and company. Let’s go ALRT!
Yeah. I'm sure Chan would like to sell you a few million shares right now at 5¢. Go for it, big shooter. What's holding you back?
Rdizz - yes sir. I mean, what's $25K to a big shooter like johnglenn when he stands to become a zillionaire any day now? LOL. GLTU!
If you think it's going to skyrocket than even .10 would seem like a sale.
Not trying to argue, just being silly
Called my bluff? lol What bluff.
I can buy at .05 now and per the previous offer sounds like I can buy more at .05 in the future.
I would be willing to make a side wager that McVee will have an opportunity to sell at .08 cents.
LOL. Dollarland any day now!
Lol, called his bluff
LOL! Well, if you're so confident we're headed to dollar-land any day now, why not just buy my shares for $0.10 right now? Sounds like a steal to me
We will be having a party. Cant wait.
We will be celebrating a much higher pps and you selling all your shares.
Although I will kind of miss having you around.
You know the old story about Ifs and Buts, Candy and Nuts.
If they announce a partnership with a major pharma company you will get your .08 cents.
Looking forward to it.
My apologies. Checked limit and it's set at 08 (not 07), AON
Followers
|
148
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
13396
|
Created
|
10/05/09
|
Type
|
Free
|
Moderators |
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |